Ligand Sees 2024 Core Adj. EPS $5.00-$5.50 vs $5.16 Est., Sees Total Revenue $140M-$157M vs $147.17M Est.
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals (LGND) has provided its financial outlook for 2024, projecting core adjusted EPS between $5.00 and $5.50, compared to the estimated $5.16. The company also expects total revenue to be in the range of $140 million to $157 million, against the estimated $147.17 million.
August 06, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ligand Pharmaceuticals (LGND) has provided its financial outlook for 2024, projecting core adjusted EPS between $5.00 and $5.50, compared to the estimated $5.16. The company also expects total revenue to be in the range of $140 million to $157 million, against the estimated $147.17 million.
The financial outlook provided by Ligand Pharmaceuticals is generally in line with or slightly better than market expectations. The EPS range is close to the estimate, and the revenue range encompasses the estimate, suggesting stable or slightly positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100